Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer-Reference-Cited by-同舟云学术

Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer

Published:2017-09-28 Issue:3 Volume:243 Page:307-319
ISSN:0022-3417
Container-title:The Journal of Pathology
language:en
Short-container-title:J. Pathol

Author:

Noh Ka-Won¹²^ORCID,Lee Mi-Sook¹²,Lee Seung Eun³,Song Ji-Young²,Shin Hyun-Tae¹⁴,Kim Yu Jin²,Oh Doo Yi²,Jung Kyungsoo¹²,Sung Minjung²,Kim Mingi¹²,An Sungbin¹²,Han Joungho⁵,Shim Young Mog⁶,Zo Jae Ill⁶,Kim Jhingook⁶,Park Woong-Yang¹⁴,Lee Se-Hoon¹⁷,Choi Yoon-La¹²⁵

Affiliation:

1. Department of Health Sciences and Technology, SAIHST; Sungkyunkwan University School of Medicine; Seoul Korea

2. Laboratory of Cancer Genomics and Molecular Pathology; Samsung Medical Center, Sungkyunkwan University School of Medicine; Seoul Korea

3. Department of Pathology; Konkuk University School of Medicine; Seoul Korea

4. Samsung Genomic Institute; Samsung Medical Center; Seoul Korea

5. Department of Pathology and Translational Genomics, Samsung Medical Center; Sungkyunkwan University School of Medicine; Seoul Korea

6. Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center; Sungkyunkwan University School of Medicine; Seoul Korea

7. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center; Sungkyunkwan University School of Medicine; Seoul Korea

Funder

Ministry of Science ICT and Future Planning

National Research Foundation of Korea

Publisher

Wiley

Subject

Pathology and Forensic Medicine

Reference27 articles.

1. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer;Kwak;N Engl J Med,2010

2. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer;Shaw;N Engl J Med,2013

3. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers;Katayama;Sci Transl Med,2012

4. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond;Awad;Clin Adv Hematol Oncol,2014

5. First-line crizotinib versus chemotherapy in ALK-positive lung cancer;Solomon;N Engl J Med,2014

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EML4-ALK variant-specific genetic interactions shape lung tumorigenesis;2024-08-27

2. Tyrosine kinase inhibitors in cancers: Treatment optimization – Part I;Critical Reviews in Oncology/Hematology;2024-07

3. Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database;Journal of Thoracic Oncology;2024-07

4. Clinical difference on the variants and co-mutation in a Chinese cohort with ALK-positive advanced non-small cell lung cancer;Clinical and Translational Oncology;2024-04-18

5. Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers;2024-01-17